News

Wall Street expects no quarterly revenue and a GAAP loss of $0.04 per share, narrowing from $0.05 previously.

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

Vontobel cut its holding by 16% but retained SLS shares worth $2.17 million.

Opus Capital held 385,604 shares worth about $5.69 million after increasing its position by 11.3%.

A new Schedule 13G filing showed Vanguard Capital Management owned 9.67 million SLS shares as of June 30, 2026.

New York State Common Retirement Fund boosted its holding by 70%, while Commonwealth and Axxcess each raised stakes by about 17%.

An arbitrator recently dismissed Sellas’ claims against 3D Medicines and ordered about $1 million in legal-cost payments.

Sellas estimated cash and cash equivalents of $138.3 million as of June 30.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.

During an interview on Fox & Friends on Friday, Stergiou said AI will play a major role in helping cure cancer by enabling more precise treatments.

A new MD Anderson study found that survival was significantly shorter among older and higher-risk AML patients.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

Sellas is preparing for database lock, potential BLA-related regulatory work, and development of SLS009, its second AML drug.

The company entered a quiet period for trial-specific updates ahead of topline data.

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

Earlier this week, SELLAS Life Sciences Group highlighted that its REGAL Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia has reached 78 of the 80 required overall survival events, bringing the pivotal data readout within sight. Investor interest has also been shaped by amended executive employment agreements that include change-of-control benefits, feeding speculation about potential corporate developments alongside the awaited GPS results. With the REGAL Phase 3 GPS data...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet the stock currently screens as expensive on broad valuation checks. This sets up a clear tension between recent share price strength and what the fundamentals suggest about value. Over 3 years, the stock has returned close to 7x, which puts extra focus on whether that gain is supported by fundamentals or mainly by sentiment. Expectations for strong revenue and earnings growth, combined with a sizeable shelf registration...

SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid leukemia approaches the required events for an overall survival readout, a key catalyst for the stock. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.19, SELLAS Life Sciences Group has seen a 69.97% 1 month share price return and a 203.22% year to date share price return. The 1 year total shareholder return is very large, signaling that...

Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]

CEO Angelos Stergiou said he will discuss “novel clinical developments” involving GPS and SLS009 on Fox & Friends.

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

CEO Angelos Stergiou said slower event accrual may signal a “highly effective active arm.”

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm […]

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.

Gamma Investing cut its SLS stake by 259 shares, or 32%, holding 556 shares worth about $8,210 as of June 30.